MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Visiongain
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report - A new report by visiongain, a London-based business information company, predicts that global revenues for biosimilars will reach $1.6 billion in 2012
World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/04/10 - A new report by visiongain, a London-based business information company, predicts that global revenues for biosimilars will reach $1.6 billion in 2012.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Visiongain forecasts that monoclonal antibodies will become the largest sector of the biosimilars market by 2022. Biosimilar monoclonal antibodies will reach developed markets, such as the US and the EU, by the middle of the decade, with Roche’s Rituxan likely to be the first target. By 2016, revenues for the segment will reach $849m. By then, however, biosimilar insulin and insulin analogues will be the largest sector of the market, having grown since 2011 with a CAGR of 41.4%.

Richard Lang, a pharmaceutical industry analyst at visiongain, said: “Biosimilars are an exciting opportunity for companies seeking to enter or maintain a presence in the biopharmaceutical industry. Sandoz and Teva are the major players in developed markets currently, although their position will be challenged in the near future by many other generics and Big Pharma companies. Merck & Co.’s potential $720m deal with Hanwha Chemical shows the level of money companies are willing to invest in this fast-growing market.”

This study forecasts revenues of six leading segments of the biosimilar market. In 2011, erythropoietins, G-CSF and growth hormones accounted for 42.1%. Products from these sectors are available in most major developed and emerging markets, although uptake is varied for each class. Sandoz’ Omnitrope (somatropin), for example, accounts for less than 5% of the US growth hormones market.

The new report also discusses leading national markets for biosimilars. In 2011, China was the largest national market, although with around 150 players, the market there is fragmented. The US market will remain small in 2012, as patents continue to cover many leading biologics. However, the release of draft development guidelines by the FDA in February 2012, as well as patent expiries from 2014 onwards, will cause strong growth towards the middle of the decade. By 2022, the US will be the world’s second largest market for biosimilars.

Rising incidence of diseases, cost restrictions by healthcare payers and biologic patent expiries will all act as growth drivers for this rapidly expanding industry and market. Increasing interest from leading pharmaceutical companies, multinational generics manufacturers and biotechnology companies will give strong growth for the world biosimilar market from 2012 onwards. Biosimilars and Follow-On Biologics: World Market 2012-2022 adds to visiongain’s range of analytical research reports on the biopharmaceutical industry.

For sample pages and further information concerning the visiongain report the Biosimilars and Follow-On Biologics: World Market 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


World Biosimilars Market to Reach $1.6 Billion in 2012 According to New Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa
Global Biosimilars Market Poised to Grow At Chart-topping Levels with a CAGR of 17.3%, Reaching .2 Billion by 2026 Finds Frost & Sullivan
Technological Advancements in Manufacturing Boost the Cell and Gene Therapy Market Says Frost & Sullivan
Huami Corp and Royal DSM Announce Collaboration on Wearable Technologies and Health Tracking for Personalized Nutrition
DSM Expands Animal Nutrition & Health Operations in China with Opening of Seventh Premix Plant
Biosurfactants and Natural Preservatives Drive Innovation for Functional Ingredients in Personal Care Market Finds Frost & Sullivan
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors
DSM Unveils Purpose-led Brand Strategy Marking Transition to End-to-end Partner in Nutrition and Health
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)